Public Release: 

Insilico to present the latest advances in AI for drug discovery at Advanced Pharma Analytics Summit

InSilico Medicine, Inc.


IMAGE: Insilico's Sr Research Scientist, Polina Mamoshina, will present with the lecture 'Deep Learning for Drug Discovery: Applying Deep Adversarial Autoencoders for New Molecule Development' at the Advanced Pharma Analytics Europe.... view more 

Credit: Insilico Medicine

Tuesday, January 16th, 2018, Baltimore, MD - Insilico Medicine, a Baltimore-based next-generation artificial intelligence company specializing in the application of deep learning for drug discovery, announces the presentation of Polina Mamoshina, Senior Research Scientist involved in multiple deep learning projects at the Pharmaceutical Artificial Intelligence division of Insilico Medicine, at 5th annual Advanced Pharma Analytics Europe Summit, January 31, 2018.

The presentation will cover the recent advances in the applications of generative adversarial networks (GANs) for new molecules development in drug discovery. The fundamental principle of GANs is adversarial training based on game theory results: competition between the Generative and Discriminative networks leads to joint evolution and almost perfect results. Insilico Medicine was the first company to integrate the advances of GAN architecture into a comprehensive drug discovery pipeline with the goal to enable the deep neural networks to produce perfect molecules for the specific set of diseases including different cancers, neurodegenerative diseases such as Alzheimer's disease, virus infections, and more.

"It is a privilege for me to speak alongside the leaders in the industry at the 5th annual Advanced Pharma Analytics event. As usual, it brings together thought experts to discuss new technologies on drug discovery. Technologies based on AI have a great potential to change drug discovery process dramatically mainly by speeding it up introducing a limited amount of highly promising molecules instead of thousands with unknown activities and possibly increase the drug space, finding new drugs, a new mechanism of action, new chemistry", said Polina Mamoshina, Senior Research Scientist in Insilico Medicine, Inc.

"Generative adversarial networks (GANs) revolutionised deep learning and found its applications in several areas, including realistic image synthesis, text-to-image synthesis or even animating movie, etc Vast amounts of data collected within pharmaceutical industry can be utilised to build similar models. Nowadays, the target itself is not a competitive advantage, in most cases the value is in a molecule. At Insilico Medicine, we build GANs that work on multiple representations of the chemical structures to expand and navigate through the chemical space. Automated discovery of novel chemotypes with certain properties against specific targets offered by GANs shows a great promise to significantly facilitate early drug design stages", said Alex Aliper, President of EMEA in Insilico Medicine, Inc.

The 5th annual Advanced Pharma Analytics Europe Summit is dedicated to supporting the growing biopharmaceutical community and provides opportunities to showcase advanced pipelines to maximize successful outcomes with cutting-edge data science and analytics. The meeting will transpire 30-31 of January 2018.

Insilico Medicine is the first company applied deep generative adversarial networks (GANs) to the generation of new molecular structures with specified parameters and published seminal papers in Oncotarget and Molecular Pharmaceutics. Another paper published in Molecular Pharmaceutics in 2016 and demonstrated the proof of concept of the application of deep neural networks for predicting the therapeutic class of the molecule using the transcriptional response data, received the American Chemical Society Editors' Choice Award. One of the recent papers published in November 2017 described the application of the next-generation AI and blockchain technologies to return the control over personal data back to the individual.

The latest paper published in the Journals of Gerontology exhibited the new artificial intelligence algorithm determining the biological age with high precision and having a potential to reveal whether lifestyle changes and medicinal products can increase people's chances of living a long and healthy life.


For further information, images or interviews, please contact:

Contact: Qingsong Zhu, PhD

Official Summit Website:

About Insilico Medicine, Inc

Insilico Medicine, Inc. is an artificial intelligence company headquartered at the Emerging Technology Centers at the Johns Hopkins University Eastern campus in Baltimore, with R&D and management resources in Belgium, Russia, UK, Taiwan and Korea sourced through hackathons and competitions.

The company utilizes advances in genomics, big data analysis, and deep learning for in silico drug discovery and drug repurposing for aging and age-related diseases. Insilico pioneered the applications of the generative adversarial networks (GANs) and reinforcement learning for generation of novel molecular structures for the diseases with a known target and with no known targets. In addition to working collaborations with the large pharmaceutical companies, the company is pursuing internal drug discovery programs in cancer, dermatological diseases, fibrosis, Parkinson's Disease, Alzheimer's Disease, ALS, diabetes, sarcopenia, and aging. Through a partnership with the company launched a range of nutraceutical products compounded using the advanced bioinformatics techniques and deep learning approaches. It also provides a range of consumer-facing applications including Young.AI and Aging.AI and operates Chemistry.AI intended to capture the tacit knowledge of medicinal chemists.

Through a partnership with the BitFury Group, the company is working on a range of AI solutions for blockchain to help return the power over life data back to the individual. The company raised venture capital and partnered with Juvenescence Limited, a holding company focused on longevity biotechnology. The company aspires to become the "Bell Labs" for artificial intelligence and associated technologies for healthcare and longevity biotechnology and commercialize its research by forming subsidiaries around the specific technologies and licensing the intellectual property, molecules and data to the biotechnology and pharmaceutical companies. In 2017, NVIDIA selected Insilico Medicine as one of the Top 5 AI companies in its potential for social impact. In 2018, the company was named the one of the global top 100 AI companies by CB Insights. Brief company video:

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.